[SCHEDULE 13G/A] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Frazier-affiliated funds disclose their holdings in Disc Medicine (Common Stock, CUSIP 254604101). The largest single holding reported is 1,026,489 shares (3.0% of the class) held directly by Frazier Life Sciences Public Fund, L.P., with shared voting and dispositive power. Other direct holdings include 300,643 shares (0.9%) by Frazier Life Sciences Public Overage Fund, L.P., 264,484 shares (0.8%) by Frazier Life Sciences XI, L.P., and 63,218 shares (0.2%) by Frazier Life Sciences X, L.P.

The filing clarifies governance and attribution: several entities report shared voting and shared dispositive power over these positions and the Statement corrects any prior over-attribution of ownership to certain committee members. Percentages are calculated using 34,634,295 shares outstanding as stated in the filing.

Positive

• Clarification and correction of prior attributions reduces overstated beneficial ownership for individual committee members
• Detailed disclosure of shared voting and dispositive power provides clearer governance transparency

Negative

• None.

Insights

Financial Analyst

TL;DR Frazier entities hold small, non-control stakes (all below 5%), and the filing clarifies prior attribution errors.

The largest reported position is 1,026,489 shares (3.0%) held by Frazier Life Sciences Public Fund, L.P., with other Frazier funds holding between 0.2% and 0.9%. All reported holdings are stated as shared voting and dispositive power for the listed entities where applicable. The filing also explicitly corrects prior attributions to individual committee members, reducing previous overstatements of beneficial ownership. Given each position is below the 5% reporting threshold for control implications, the disclosure is primarily informational and governance-clarifying rather than indicative of control or a coordinated group.

Corporate Governance Expert

TL;DR The filing emphasizes accurate attribution of voting and dispositive power and denies group formation for control purposes.

The Statement clarifies that general partners and investment committees for several Frazier entities manage the funds and that members of those committees are not to be attributed beneficial ownership of the funds' holdings. Reporting Persons state that the filing should not be construed as an admission of beneficial ownership under Sections 13(d)/(g) or as forming a group. These formal clarifications matter for governance and proxy contexts because they limit individual attribution of fund-held shares and correct previously overstated ownership positions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

DISC MEDICINE, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

254604101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,026,489.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,026,489.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,026,489.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,026,489.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,026,489.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,026,489.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,026,489.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,026,489.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,026,489.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Frazier Life Sciences Public Overage Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 300,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 300,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

300,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLSP Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 300,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 300,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

300,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLSP Overage, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 300,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 300,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

300,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Frazier Life Sciences X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 63,218.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 63,218.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

63,218.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLS X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 63,218.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 63,218.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

63,218.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLS X, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 63,218.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 63,218.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

63,218.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 264,484.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 264,484.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

264,484.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 264,484.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 264,484.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

264,484.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 264,484.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 264,484.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

264,484.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

James N. Topper

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 63,218.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 63,218.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

63,218.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 63,218 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Patrick J. Heron

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 63,218.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 63,218.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

63,218.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 63,218 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025.

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Albert Cha

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

James Brush

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 254604101

1

Names of Reporting Persons

Daniel Estes

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DISC MEDICINE, INC.
(b)	Address of issuer's principal executive offices: 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472.
Item 2.
(a)	Name of person filing: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
(b)	Address or principal business office or, if none, residence: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304
(c)	Citizenship: The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 254604101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 1,026,489 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 300,643 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS X directly holds 63,218 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 264,484 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)	Percent of class: The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	08/14/2025

FHMLSP, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	08/14/2025

FHMLSP, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:	08/14/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:	08/14/2025

FHMLSP Overage, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:	08/14/2025

FHMLSP Overage, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:	08/14/2025

Frazier Life Sciences X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:	08/14/2025

FHMLS X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:	08/14/2025

FHMLS X, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:	08/14/2025

Frazier Life Sciences XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	08/14/2025

FHMLS XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	08/14/2025

FHMLS XI, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:	08/14/2025

James N. Topper

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/14/2025

Patrick J. Heron

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/14/2025

Albert Cha

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/14/2025

James Brush

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/14/2025

Daniel Estes

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of June 25, 2024, incorporated by reference into this Statement.

FAQ

How many shares does Frazier Life Sciences Public Fund, L.P. report owning in Disc Medicine (IRON)?

The filing reports 1,026,489 shares held directly by Frazier Life Sciences Public Fund, L.P., representing 3.0% of the common stock.

What basis was used to calculate the ownership percentages in the IRON Schedule 13G/A?

Percentages are calculated using 34,634,295 shares outstanding as stated in the filing.

Which other Frazier entities hold shares and how many?

Other reported direct holdings include 300,643 shares (0.9%) by Frazier Life Sciences Public Overage Fund, L.P., 264,484 shares (0.8%) by Frazier Life Sciences XI, L.P., and 63,218 shares (0.2%) by Frazier Life Sciences X, L.P.

Do the Reporting Persons claim sole voting or dispositive power over the shares?

No. The cover pages show 0 sole voting power and 0 sole dispositive power for the listed Reporting Persons, with the relevant amounts reported as shared voting and shared dispositive power.

Does the filing state that the Reporting Persons form a group or seek control of Disc Medicine (IRON)?

The filing states that, except as specifically noted, it should not be construed as an admission that any Reporting Person is the beneficial owner of the securities or a member of a 'group' under Sections 13(d)/(g).

Who signed the Schedule 13G/A on behalf of the Frazier reporting entities?

The filing is signed by Steve R. Bailey, as CFO of the relevant Frazier entities and as attorney-in-fact where noted.